ETCTN Trials by Disease/ Treatment Area: Breast Cancer

**Breast Cancer**

- **Triplet negative breast cancer (TNBC)**
  - Locally advanced/ metastatic TNBC
  - Hormone receptor positive (HR+)
  - With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)
  - Bone metastatic breast cancer (TNBC or ER+ and/or PR+)
  - Advanced metastatic or recurrent tumors with pathogenic BRCA 1/2 mutated

- **Hormone receptor positive (HR+)**
  - Locally advanced/ metastatic ER+ and/or PR+/HER2

- **TNBC or HR+**

- **BRCA Mutant**

---

**Triplet negative breast cancer (TNBC)**

**Locally advanced/ metastatic TNBC**

**Hormone receptor positive (HR+)**

**Locally advanced/ metastatic ER+ and/or PR+/HER2**

**TNBC or HR+**

**With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)**

**Bone metastatic breast cancer (TNBC or ER+ and/or PR+)**

**Advanced metastatic or recurrent tumors with pathogenic BRCA 1/2 mutated**

---

**10287**: A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

**10546**: Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer

**10525**: A Phase Ib Trial of ZEN-3694 with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer

**10382**: A Phase III Trial Evaluating the Safety and Efficacy of ErbB3 in Combination with Copanlisib in Patients with Triple Negative Breast Cancer (Phase 1: limited; Phase 2: ETCTN-wide)

**10146**: Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer

**10449**: A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer

**10480**: Phase I/II Study of EPA-Based EphA2 Targeted Therapy for Patients with Metastatic Triple-Negative Inflammatory Breast Cancer (limited for Phase Ib only)

**10291**: A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer (Phase 1: limited; Phase 2: ETCTN-wide)

**10302**: Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

**10529**: A 1b Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer

**10531**: A Phase II Trial of Anti-CD47 Magrolimab in Combination with Olaparib in BRCA Mutant Patients with Metastatic or Recurrent Solid Tumors (Ovarian cancer, Prostate cancer and Breast cancer)

**10546**: Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer

**10551**: Phase I/II Study of Anti-CD47 Magrolimab in Combination with Olaparib in BRCA Mutant Patients with Metastatic or Recurrent Solid Tumors (Ovarian cancer, Prostate cancer and Breast cancer)

---

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: November 10, 2022